Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Role of ST2 in Acute Pancreatitis

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT01315613
First received: March 11, 2011
Last updated: March 14, 2011
Last verified: September 2008

March 11, 2011
March 14, 2011
January 2005
September 2008   (final data collection date for primary outcome measure)
Concentration of soluble ST2 in serum [ Time Frame: Within 30 days after onset of acute pancreatitis ] [ Designated as safety issue: No ]
Concentration of soluble ST2 will be assessed in the serum of patient with an episode of acute pancreatitis, on the day of admission to the hospital as well as 24h, 48h, 7 days and 30 days later.
Same as current
Complete list of historical versions of study NCT01315613 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Role of ST2 in Acute Pancreatitis
Study of ST2-IL-33 Pathway in Acute Pancreatitis

Acute pancreatitis is characterized by an inflammatory storm which regulatory pathways are not well known. The IL-1 cytokine family is activated early during acute pancreatitis and secretion of alarmins is speculated during pancreatic necrosis. IL-33 is a member of the IL-1 family, it can act as an alarmin and its receptor, ST2, is known to sequester MyD88 which might regulate the acute pancreatitis inflammatory storm. The aim of this study is to investigate ST2 pathway in human acute pancreatitis and in murine experimental models of acute pancreatitis.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients of Erasme University Hospital

Acute Pancreatitis
Not Provided
Acute pancreatitis
Patients admitted in our institution for an episode of acute pancreatitis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Time to take blood sample less than 24h after the onset of symptoms of AP
  • Two of the following: typical pain, amylase and lipase concentrations more than 3x the upper normal limit, compatible modifications on imaging techniques

Exclusion Criteria:

  • Chronic pancreatitis
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01315613
RO-ST2
Not Provided
Romy Ouziel,, Erasme Hospital
Erasme University Hospital
Not Provided
Principal Investigator: Romy Ouziel, MD Erasme Hospital
Erasme University Hospital
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP